A genome-scale drug discovery pipeline uncovers therapeutic targets and a unique p97 allosteric binding site in Schistosoma mansoni
Open Access
- 29 August 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (35)
Abstract
Schistosomes are parasitic flatworms that infect more than 200 million people globally. However, there is a shortage of molecular tools that enable the discovery of potential drug targets within schistosomes. Thus, praziquantel has remained the frontline treatment for schistosomiasis despite known liabilities. Here, we have conducted a genome-wide study in Schistosoma mansoni using the human druggable genome as a bioinformatic template to identify essential genes within schistosomes bearing similarity to catalogued drug targets. Then, we assessed these candidate targets in silico using a set of unbiased criteria to determine which possess ideal characteristics for a ready-made drug discovery campaign. Following this prioritization, we pursued a parasite p97 ortholog as a bona-fide drug target for the development of therapeutics to treat schistosomiasis. From this effort, we identified a covalent inhibitor series that kills schistosomes through an on-target killing mechanism by disrupting the ubiquitin proteasome system. Fascinatingly, these inhibitors induce a conformational change in the conserved D2 domain P-loop of schistosome p97 upon modification of Cys519. This conformational change reveals an allosteric binding site adjacent to the D2 domain active site reminiscent of the “DFG” flip in protein kinases. This allosteric binding site can potentially be utilized to generate new classes of species-selective p97 inhibitors. Furthermore, these studies provide a resource for the development of alternative therapeutics for schistosomiasis and a workflow to identify potential drug targets in similar systems with few available molecular tools.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI167967)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI150776)
- Welch Foundation (I-1948-20240404)
This publication has 98 references indexed in Scilit:
- 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletionAnnals of Oncology, 2022
- A targeted covalent inhibitor of p97 with proteome-wide selectivityActa Pharmaceutica Sinica B, 2021
- Clustal Omega for making accurate alignments of many protein sequencesProtein Science, 2017
- The AAA ATPase Vps4 Plays Important Roles in Candida albicans Hyphal Formation and is Inhibited by DBeQMycopathologia, 2015
- Praziquantel: Too Good to be Replaced?2012
- PraziquantelParasitology Research, 2003
- Cathepsin B-like activity predominates over cathepsin L-like activity in adult Schistosoma mansoni and S. japonicumParasitology Research, 1997
- Antischistosomal drugs: Past, present … and future?Pharmacology & Therapeutics, 1995
- Inhibition of rat liver transglutaminase by nucleotidesCellular and Molecular Life Sciences, 1991
- Distantly related sequences in the alpha‐ and beta‐subunits of ATP synthase, myosin, kinases and other ATP‐requiring enzymes and a common nucleotide binding fold.The EMBO Journal, 1982